Indivior Pharmaceuticals, Inc. INDV Operating lease right-of-use asset amortization

Operating lease right-of-use asset amortization at other companies

JAN

Janus Living JAN

——

Other financials

Income statement

See full

Revenue$317.0M+19.2%

Gross profit$277.0M+24.8%

Operating income$137.0M+108%

Net income$89.0M+89.4%

EPS (diluted)$0.69+81.6%

Balance sheet

See full

Cash & equivalents$175.0M-53.0%

Total debt$509.0M+37.6%

Total equity-$144.0M+49.5%

Total assets$1.2B-12.9%

Cash flow

See full

Operating cash flow-$9.0M-112%

CapEx$20.0M+300%

Free cash flow-$29.0M-141%

Valuation

See full

Market cap$4.53B+213%

Enterprise value$4.86B+242%

P/E18×—

P/S3.5×+2.3×

Profitability

See full

Gross margin81.3%+1.5pp

Operating margin25.8%+23.3pp

Net margin19.4%+18.9pp

FCF margin-14.9%—

Returns & leverage

See full

Return on equity-117%—

Debt / equity-3.5×—

Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's operating lease right-of-use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's operating lease right-of-use asset amortization?: Indivior Pharmaceuticals, Inc. (INDV) reported operating lease right-of-use asset amortization of $2M in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's operating lease right-of-use asset amortization changed year-over-year?: Indivior Pharmaceuticals, Inc. 's operating lease right-of-use asset amortization decreased by 0.0% year-over-year, from $2M to $2M.